Takeda Pharmaceutical Company Limited (TYO:4502)
4,398.00
-4.00 (-0.09%)
Aug 27, 2025, 11:30 AM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.11T JPY in the quarter ending June 30, 2025, a decrease of -8.39%. This brings the company's revenue in the last twelve months to 4.48T, up 1.52% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4,480.25B
Revenue Growth
+1.52%
P/S Ratio
1.53
Revenue / Employee
94.41M
Employees
47,455
Market Cap
6,875.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.21B |
Daiichi Sankyo Company | 1,924.68B |
HOYA Corporation | 876.09B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |
Olympus | 969.02B |
Takeda Pharmaceutical Company News
- 4 days ago - What's Going On With Takeda Stock On Friday? - Benzinga
- 4 days ago - What's Going On With Takeda Stock On Friday? - Benzinga
- 5 days ago - Japan's Takeda weighs India for global trials to speed up drug launches - Reuters
- 18 days ago - Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis - Newsfile Corp
- 27 days ago - Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales - Benzinga
- 27 days ago - Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales - Benzinga
- 27 days ago - Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Takeda Pharmaceutical Non-GAAP EPS of ¥151.00, revenue of ¥1106.7B; reaffirms FY outlook - Seeking Alpha